Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 136 to 150 of 407 results for infection control

  1. Genedrive MT-RNR1 ID Kit for detecting a genetic variant to guide antibiotic use and prevent hearing loss in babies: early value assessment (HTG665)

    Early value assessment (EVA) guidance on the Genedrive MT-RNR1 ID Kit for detecting a genetic variant to guide antibiotic use and prevent hearing loss in babies.

  2. Rapid tests for group A streptococcal infections in people with a sore throat (HTG531)

    Evidence-based recommendations on rapid tests for group A streptococcal infections in people aged 5 and over with a sore throat.

  3. Dapagliflozin in triple therapy for treating type 2 diabetes (TA418)

    Evidence-based recommendations on dapagliflozin (Forxiga) given with 2 other drugs for treating type 2 diabetes in adults.

  4. Ertugliflozin as monotherapy or with metformin for treating type 2 diabetes (TA572)

    Evidence-based recommendations on ertugliflozin (Steglatro) as monotherapy or with metformin for treating type 2 diabetes in adults.

  5. Intralesional photocoagulation of subcutaneous congenital vascular disorders (HTG56)

    Evidence-based recommendations on intralesional photocoagulation of subcutaneous congenital vascular disorders. This involves inserting a laser fibre into the lesion to deliver the light deep within it.

  6. Multiple sclerosis in adults: management (NG220)

    This guideline covers diagnosing and managing multiple sclerosis in people aged 18 and over. It aims to improve the quality of life for people with multiple sclerosis by promoting prompt and effective symptom management and relapse treatment, and comprehensive reviews.

  7. Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy (TA329)

    Evidence-based recommendations on infliximab (Remicade, Inflectra or Remsima), adalimumab (Humira) and golimumab (Simponi) for treating moderate to severe ulcerative colitis in adults, and on infliximab for treating severe active ulcerative colitis in children and young people of 6–17 years.

  8. AdenoPlus point-of-care test for diagnosing adenoviral conjunctivitis (MIB46)

    NICE has developed a medtech innovation briefing (MIB) on the AdenoPlus point-of-care test for diagnosing adenoviral conjunctivitis

  9. Bair Hugger for measuring core temperature during perioperative care (MIB99)

    NICE has developed a medtech innovation briefing (MIB) on Bair Hugger for measuring core temperature during perioperative care .

  10. Mosaicplasty for symptomatic articular cartilage defects of the knee (HTG463)

    Evidence-based recommendations on mosaicplasty in people with symptomatic articular cartilage defects of the knee. This involves taking healthy cartilage from the edge of the joint and inserting it into drilled tunnels in the damaged site.

  11. The Versajet II hydrosurgery system for surgical debridement of acute and chronic wounds and burns (MIB1)

    NICE has developed a Medtech Innovation Briefing (MIB) on the Versajet II hydrosurgery system

  12. Prontosan for treating acute and chronic wounds (HTG616)

    Evidence-based recommendations on Prontosan for treating acute and chronic wounds.

  13. Plus Sutures for preventing surgical site infection (HTG586)

    Evidence-based recommendations on Plus Sutures for preventing surgical site infection.

  14. Cabotegravir with rilpivirine for treating HIV-1 (TA757)

    Evidence-based recommendations on cabotegravir (Vocabria) with rilpivirine (Rekambys) for treating HIV-1 in adults. This includes adults with virological suppression (HIV-1 RNA fewer than 50 copies/ml) on a stable antiretroviral regimen, and without any evidence of viral resistance to, and no previous virological failure with, any non-nucleoside reverse transcriptase inhibitors or integrase inhibitors.

  15. Fetal vesico–amniotic shunt for lower urinary tract outflow obstruction (HTG129)

    Evidence-based recommendations on fetal vesico–amniotic shunt for lower urinary tract outflow obstruction. This involves inserting a cannula through the mother's abdominal and uterine walls into the amniotic cavity and subsequently into the bladder of the fetus.